Business context and reporting period
The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022, filed November 14, 2022. This does not match the request metadata identifying Gyre Therapeutics, Inc.; verify the issuer before relying on this summary. Catalyst had ceased research and development activities and was pursuing strategic alternatives and potential distributions to stockholders.
Financial performance and position
- Revenue: Collaboration revenue was $0 for Q3 2022 and $0.8 million for the first nine months of 2022, down 100% and 84%, respectively, from comparable 2021 periods. The company reported no drug-product sales.
- Profit/loss: Q3 net loss was $4.9 million, versus a $25.2 million loss in Q3 2021. Nine-month net income was $32.2 million, versus a $67.6 million loss in 2021; the 2022 result primarily reflects a $57.2 million gain on asset disposals, not ongoing operating profitability. Q3 basic and diluted loss per share was $0.16; nine-month earnings per share was $1.02.
- Expenses and margins: Q3 R&D expense fell 96% to $0.8 million and G&A fell 10% to $4.4 million. Nine-month R&D fell 77% to $12.4 million and G&A fell 11% to $13.2 million. With no Q3 revenue, operating margin is not meaningful.
- Cash flow: Cash used in operating activities was $31.6 million for the first nine months, compared with $66.1 million in 2021. Investing activities provided $55.4 million, principally from the Vertex asset sale; financing activities used $45.0 million, principally for the special dividend. Cash decreased $21.3 million over the period.
- Liquidity and debt: At September 30, cash and cash equivalents were $23.1 million, current assets $30.2 million, current liabilities $1.6 million, and total liabilities $1.6 million. The balance sheet reports no debt. Management said available cash should cover requirements for at least 12 months from the filing date, subject to assumptions that may prove incorrect.
Material changes and unusual items
- In May 2022, Catalyst sold its complement portfolio and related intellectual property to Vertex for $60.0 million: $55.0 million received at closing and $5.0 million held back for one year subject to post-closing indemnification obligations. The sale generated a reported $57.2 million net gain; the $5.0 million hold-back was recorded in receivables.
- On September 20, 2022, the company paid a one-time $45.0 million dividend, or $1.43 per share. Cash fell from $44.3 million at year-end 2021 to $23.1 million at quarter-end.
- Biogen terminated its collaboration agreement effective May 2022. Catalyst settled outstanding disputes, including forgiving about $0.6 million of receivables and paying $10,000; a $0.6 million settlement expense was recorded in Q2.
- The company stopped R&D activities, completed workforce reductions, and terminated several vendor and facility arrangements. It reported five full-time employees after the March 2022 reduction.
Outlook, risks and contingencies
- Management is exploring sales, licenses, partnerships, or other strategic alternatives for its remaining coagulation assets: MarzAA, DalcA, and CB 2679d-GT. These assets are available for partnering; there is no assurance a transaction will occur. If no viable transaction appears likely, the company said it expects to seek stockholder approval to dissolve and return available cash.
- Management anticipated one or more future special dividends but gave no timing or amount. Distributions depend on operating and wind-down costs, taxes, severance, insurance, other liabilities, receipt of the Vertex hold-back, and proceeds from any further asset transactions.
- MarzAA trials were discontinued amid enrollment, competition, capital, and operational challenges. COVID-19 could disrupt out-licensing efforts. Use of tax-loss carryforwards may be restricted by ownership-change rules.
- Nasdaq notified the company on November 2, 2022 that its share price had failed the $1.00 minimum bid-price requirement; the initial compliance period ran through May 1, 2023. Delisting could impair share liquidity and financing access.
- Management concluded disclosure controls were ineffective because of an unremediated material weakness concerning review and GAAP accounting for employee retention bonuses. Remediation actions were underway but required further testing and validation.
- A stockholder lawsuit concerning the Vertex sale was dismissed with prejudice in August 2022; Catalyst reimbursed $0.4 million of plaintiffs’ legal and other expenses.
Important facts for investors to verify
- Confirm the filing issuer: the document is for Catalyst Biosciences, not Gyre Therapeutics.
- Check whether the $5.0 million Vertex hold-back was collected and whether any indemnification claims reduced it.
- Verify subsequent cash distributions, wind-down expenses, and the remaining cash available to stockholders.
- Track progress or outcomes for strategic alternatives involving the coagulation assets, and any dissolution proposal.
- Review subsequent Nasdaq listing status and whether the disclosed material weakness was remediated.